Cedars-Sinai provides patients with Fitbits to accelerate recovery

Cara Livernois | | Health Exec | Precision Medicine

Getting up and moving after surgery is key in achieving a healthy recovery, yet many patients lack the motivation. In response, physicians at Cedars-Sinai Hospital in Los Angeles have provided patients with Fitbit activity trackers to get patients moving.

Walking around after surgery has proven benefits in the recovery process, and taking only 1,000 steps per day can significantly reduce hospital stays. By providing Fitbits, physicians hope to motivate patients to move after surgery, effectively decreasing hospitalization time and improving overall outcomes.

“It really encourages patients to get out and walk for a reason," said Timothy Daskivich, a doctor at Cedars-Sinai.

Read the full story here:

A Los Angeles hospital is using Fitbits to help patients go home sooner

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.